
Ernexa Therapeutics Inc. Warrants (ERNAW) Stock Ticker
Market factors today
Unlock the full ERNAW picture
About Ernexa Therapeutics Inc. Warrants
Operating in the preclinical phase, Ernexa Therapeutics Inc. is dedicated to advancing therapies based on induced mesenchymal stem cells (iMSC) to combat both solid tumors and autoimmune conditions. Its primary therapeutic, ERNA-101, is an allogeneic iMSC specifically formulated to secrete pro-inflammatory cytokines like IL-7 and IL-15 for the treatment of ovarian cancer. Complementing this, ERNA-102 is another iMSC designed to deliver the anti-inflammatory cytokine IL-10, targeting rheumatoid arthritis. Ernexa Therapeutics has secured a licensing agreement with Factor Bioscience Limited. The company, founded in 2018 and headquartered in Cambridge, Massachusetts, was formerly named Eterna Therapeutics Inc., before officially changing to Ernexa Therapeutics in March 2025.
ERNAW stock facts
| Ticker symbol | ERNAW |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $275,644 |
| CEO | Sanjeev Luther |
| Employees | 5 |
| Headquarters | Cambridge, MA, US |
| IPO date | 2024-07-12 |
| Website | www.ernexatx.com |
What you can see for ERNAW on Tickr
Live ERNAW price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ERNAW report.
Rankings
FAQ
What is the ticker symbol for Ernexa Therapeutics Inc. Warrants?
The ticker symbol for Ernexa Therapeutics Inc. Warrants is ERNAW, listed on the NASDAQ Capital Market.
What is ERNAW?
Operating in the preclinical phase, Ernexa Therapeutics Inc. is dedicated to advancing therapies based on induced mesenchymal stem cells (iMSC) to combat both solid tumors and autoimmune conditions. Its primary therapeutic, ERNA-101, is an allogeneic iMSC specifically formulated to secrete pro-inflammatory cytokines like IL-7 and IL-15 for the treatment of ovarian cancer. Complementing this,…